Devinder S Dhindsa1, Anurag Mehta1, Pratik B Sandesara1, Aneesha Thobani2, Stephen Brandt3, Laurence S Sperling4. 1. Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Department of Medicine, Emory University School of Medicine, 1365 Clifton Road, NE, Building A, Suite 2200, Atlanta, GA, 30322, USA. 2. Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA, USA. 3. Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. 4. Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Department of Medicine, Emory University School of Medicine, 1365 Clifton Road, NE, Building A, Suite 2200, Atlanta, GA, 30322, USA. lsperli@emory.edu.
Abstract
PURPOSE OF REVIEW: This review will serve to highlight the clinical rationale used in the selection of sodium-glucose cotransporter 2 inhibitors (SGLT2-i) or glucagon-like peptide 1 receptor agonists (GLP1-ra). RECENT FINDINGS: SGLT2-i and GLP1-ra are the first anti-hyperglycemics to demonstrate significant cardiovascular benefit in multiple cardiovascular outcomes trials (CVOTs), with benefits that are consistent across class of medication. Diabetes is a major risk factor for morbidity and mortality from cardiovascular disease. Sodium-glucose cotransporter 2 inhibitors (SGLT2-i) and glucagon-like peptide 1 receptor agonists (GLP1-ra) are the first anti-hyperglycemics to demonstrate significant cardiovascular benefit. Given the unique side effect and benefit profiles, appropriate consideration of these agents with a focus on cardiovascular risk reduction requires an individualized approach.
PURPOSE OF REVIEW: This review will serve to highlight the clinical rationale used in the selection of sodium-glucose cotransporter 2 inhibitors (SGLT2-i) or glucagon-like peptide 1 receptor agonists (GLP1-ra). RECENT FINDINGS:SGLT2-i and GLP1-ra are the first anti-hyperglycemics to demonstrate significant cardiovascular benefit in multiple cardiovascular outcomes trials (CVOTs), with benefits that are consistent across class of medication. Diabetes is a major risk factor for morbidity and mortality from cardiovascular disease. Sodium-glucose cotransporter 2 inhibitors (SGLT2-i) and glucagon-like peptide 1 receptor agonists (GLP1-ra) are the first anti-hyperglycemics to demonstrate significant cardiovascular benefit. Given the unique side effect and benefit profiles, appropriate consideration of these agents with a focus on cardiovascular risk reduction requires an individualized approach.
Authors: Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: David Z I Cherney; Bruce A Perkins; Nima Soleymanlou; Maria Maione; Vesta Lai; Alana Lee; Nora M Fagan; Hans J Woerle; Odd Erik Johansen; Uli C Broedl; Maximilian von Eynatten Journal: Circulation Date: 2013-12-13 Impact factor: 29.690
Authors: Julio Rosenstock; Ante Jelaska; Guillaume Frappin; Afshin Salsali; Gabriel Kim; Hans J Woerle; Uli C Broedl Journal: Diabetes Care Date: 2014-06-14 Impact factor: 19.112
Authors: Ilkka Tikkanen; Kirsi Narko; Cordula Zeller; Alexandra Green; Afshin Salsali; Uli C Broedl; Hans J Woerle Journal: Diabetes Care Date: 2014-09-30 Impact factor: 19.112
Authors: Lotte Bjerre Knudsen; Lars Wichmann Madsen; Søren Andersen; Kasper Almholt; Anne S de Boer; Daniel J Drucker; Carsten Gotfredsen; Frederikke Lihme Egerod; Anne Charlotte Hegelund; Helene Jacobsen; Søren Dyring Jacobsen; Alan C Moses; Anne-Marie Mølck; Henriette S Nielsen; Jette Nowak; Helene Solberg; Tu D L Thi; Milan Zdravkovic; Ulrik Moerch Journal: Endocrinology Date: 2010-03-04 Impact factor: 4.736
Authors: Richard M Cubbon; Stephen B Wheatcroft; Peter J Grant; Christopher P Gale; Julian H Barth; Robert J Sapsford; Ramzi Ajjan; Mark T Kearney; Alistair S Hall Journal: Eur Heart J Date: 2007-02-08 Impact factor: 29.983
Authors: Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Mariam Elmegaard Malik; Charlotte Andersson; Paul Blanche; Maria D'Souza; Christian Madelaire; Bochra Zareini; Morten Lamberts; Søren Lund Kristensen; Naveed Sattar; John McMurray; Lars Køber; Christian Torp-Pedersen; Gunnar Gislason; Morten Schou Journal: Clin Res Cardiol Date: 2022-04-08 Impact factor: 5.460
Authors: Stephanie Niman; Jennifer Hardy; Rebecca F Goldfaden; Jessica Reid; Mae Sheikh-Ali; David Sutton; Rushab Choksi Journal: Drugs R D Date: 2021-03-26